Home > Insider Trading > Filing (0001209191-23-004118)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649989	Outlook Therapeutics Inc.	OTLK	Biological Products, (No Disgnostic Substances) (2836)	383982704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1760511	Jeff Evanson	C/O Outlook Therapeutics, Inc. 485 Route 1 South, Bldg F, Suite 320 Iselin NJ 08830	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-01-17	27,162	$1.31	1,149,968	No	4	S	Direct
Common Stock	Disposition	2023-01-18	33,738	$1.25	1,116,230	No	4	S	Direct
Common Stock	Disposition	2023-01-19	103,255	$1.22	1,012,975	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1909 - $1.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.